Cinctive Capital Management LP Decreases Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Cinctive Capital Management LP trimmed its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 62.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 33,797 shares of the biopharmaceutical company's stock after selling 57,330 shares during the quarter. Cinctive Capital Management LP owned approximately 0.05% of Celldex Therapeutics worth $1,149,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in CLDX. California State Teachers Retirement System raised its position in shares of Celldex Therapeutics by 13.5% during the first quarter. California State Teachers Retirement System now owns 58,403 shares of the biopharmaceutical company's stock worth $2,451,000 after acquiring an additional 6,929 shares during the last quarter. DNB Asset Management AS raised its position in shares of Celldex Therapeutics by 47.2% during the second quarter. DNB Asset Management AS now owns 7,872 shares of the biopharmaceutical company's stock worth $292,000 after acquiring an additional 2,523 shares during the last quarter. Mirador Capital Partners LP raised its position in shares of Celldex Therapeutics by 7.3% during the second quarter. Mirador Capital Partners LP now owns 112,379 shares of the biopharmaceutical company's stock worth $4,159,000 after acquiring an additional 7,620 shares during the last quarter. Assenagon Asset Management S.A. raised its position in shares of Celldex Therapeutics by 53.0% during the second quarter. Assenagon Asset Management S.A. now owns 139,162 shares of the biopharmaceutical company's stock worth $5,150,000 after acquiring an additional 48,231 shares during the last quarter. Finally, Values First Advisors Inc. increased its holdings in Celldex Therapeutics by 8.3% in the second quarter. Values First Advisors Inc. now owns 21,319 shares of the biopharmaceutical company's stock worth $789,000 after purchasing an additional 1,627 shares in the last quarter.

Celldex Therapeutics Trading Up 1.4 %

Shares of NASDAQ:CLDX traded up $0.36 during mid-day trading on Wednesday, hitting $26.58. 730,706 shares of the company traded hands, compared to its average volume of 882,594. The stock has a market cap of $1.76 billion, a P/E ratio of -10.34 and a beta of 1.57. Celldex Therapeutics, Inc. has a 12-month low of $22.93 and a 12-month high of $53.18. The stock has a 50-day moving average price of $28.07 and a two-hundred day moving average price of $34.16.

Insider Activity at Celldex Therapeutics

In related news, CEO Anthony S. Marucci bought 11,500 shares of the business's stock in a transaction that occurred on Monday, November 11th. The shares were bought at an average price of $26.82 per share, with a total value of $308,430.00. Following the completion of the transaction, the chief executive officer now directly owns 40,284 shares in the company, valued at approximately $1,080,416.88. This represents a 39.95 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 3.80% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Cantor Fitzgerald reiterated an "overweight" rating and issued a $67.00 target price on shares of Celldex Therapeutics in a report on Monday, September 16th. The Goldman Sachs Group assumed coverage on Celldex Therapeutics in a report on Monday, September 30th. They issued a "neutral" rating and a $45.00 target price for the company. Wolfe Research downgraded Celldex Therapeutics from an "outperform" rating to a "peer perform" rating in a report on Friday, September 27th. Citigroup assumed coverage on Celldex Therapeutics in a report on Monday, October 7th. They issued a "buy" rating and a $70.00 target price for the company. Finally, HC Wainwright reiterated a "buy" rating and issued a $80.00 target price on shares of Celldex Therapeutics in a report on Wednesday, November 20th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $62.25.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.